CDKN2A/P16 expression in mycosis fungoides

被引：0
|
作者：
Fargnoli, MC
Chimenti, S
Stanta, G
Bonin, S
Amantea, A
Felli, A
Peris, K
机构：
[1] UNIV AQUILA,DEPT DERMATOL,I-67100 LAQUILA,ITALY
[2] UNIV TRIESTE,DEPT PATHOL,I-34127 TRIESTE,ITALY
[3] INT CTR GENET ENGN & BIOTECHNOL PADRICIANO,TRIESTE,ITALY
[4] IRCCS,IST SAN GALLICANO,ROME,ITALY
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 1997年 / 109卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：487 / 487
页数：1
相关论文
共 50 条
  • [21] CDKN2A/p16 is inactivated in most melanoma cell lines
    Castellano, M
    Pollock, PM
    Walters, MK
    Sparrow, LE
    Down, LM
    Gabrielli, BG
    Parsons, PG
    Hayward, NK
    CANCER RESEARCH, 1997, 57 (21) : 4868 - 4875
  • [22] Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma
    Csepregi, Antal
    Ebert, Matthias P. A.
    Roecken, Christoph
    Schneider-Stock, Regine
    Hoffmann, Juliane
    Schulz, Hans-Ulrich
    Roessner, Albert
    Malfertheiner, Peter
    BMC CANCER, 2010, 10
  • [23] Evaluation of p16 protein expression and CDKN2A deletion in conventional and fibrosarcomatous dermatofibrosarcoma protuberans
    Siref, Andrew
    Patel, Vatsal
    Reith, John D.
    Balzer, Bonnie L.
    Shon, Wonwoo
    PATHOLOGY, 2018, 50 (04) : 474 - 475
  • [24] Small Deletions but not Methylation Underlie CDKN2A/p16 Loss of Expression in Conventional Osteosarcoma
    Mohseny, Alexander B.
    Tieken, Chris
    van der Velden, Pieter A.
    Szuhai, Karoly
    de Andrea, Carlos
    Hogendoorn, Pancras C. W.
    Cleton-Jansen, Anne-Marie
    GENES CHROMOSOMES & CANCER, 2010, 49 (12): : 1095 - 1103
  • [25] Promoter methylation of CDKN2A and lack of p16 expression characterize patients with hepatocellular carcinoma
    Antal Csepregi
    Matthias PA Ebert
    Christoph Röcken
    Regine Schneider-Stock
    Juliane Hoffmann
    Hans-Ulrich Schulz
    Albert Roessner
    Peter Malfertheiner
    BMC Cancer, 10
  • [26] Prognostic significance of p16/CDKN2A deletion in pleural mesotheliomas
    Dacic, S.
    Poppei, H. H.
    Kothmaier, H.
    Halbwedt, I.
    Morbini, P.
    Murer, B.
    Comin, C. E.
    Galateau-Salle, F.
    Demirag, F.
    Zeren, H.
    Allanoos, R.
    Gibbs, A.
    Cagle, P. T.
    MODERN PATHOLOGY, 2008, 21 : 339A - 340A
  • [27] A common variant of CDKN2A (p16) predisposes to breast cancer
    Debniak, T
    Górski, B
    Huzarski, T
    Byrski, T
    Cybulski, C
    Mackiewicz, A
    Gozdecka-Grodecka, S
    Gronwald, J
    Kowalska, E
    Haus, O
    Grzybowska, E
    Stawicka, M
    Swiec, M
    Urbanski, K
    Niepsuj, S
    Wasko, B
    Gózdz, S
    Wandzel, P
    Szczylik, C
    Surdyka, D
    Rozmiarek, A
    Zambrano, O
    Posmyk, M
    Narod, SA
    Lubinski, J
    JOURNAL OF MEDICAL GENETICS, 2005, 42 (10) : 763 - 765
  • [28] Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas
    Vivian Tang
    Rufei Lu
    Kanish Mirchia
    Jessica Van Ziffle
    Patrick Devine
    Julieann Lee
    Joanna J. Phillips
    Arie Perry
    David R. Raleigh
    Calixto-Hope G. Lucas
    David A. Solomon
    Acta Neuropathologica, 2023, 145 : 497 - 500
  • [29] Homozygous deletion of CDKN2A (p16/p14) in neuroblastomas.
    Thompson, PM
    Maris, JM
    Hogarty, MD
    Seeger, RC
    Reynolds, CP
    Brodeur, GM
    White, PS
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A327 - A327
  • [30] Comparing p16 and MTAP loss of expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
    Vizcaino, M. A.
    Mendoza, C. Zepeda
    Vaubel, R.
    Nguyen, A. T.
    Trejo-Lopez, J. A.
    Raghunathan, A.
    Jenkins, S.
    Jenkins, R.
    Giannini, C.
    BRAIN PATHOLOGY, 2023, 33
12345